• The high-level event, co-hosted in Paris on 20 June 2024 by the Government of France, the African Union and Gavi, together with Team Europe partners, will gather leaders from government, partner organisations, civil society and business across the globe, to accelerate sustainable immunisation and innovation for equitable health by 2030 and beyond, with a focus on Africa.

• The African Vaccine Manufacturing Accelerator (AVMA), an innovative financial mechanism, designed by Gavi in close collaboration with Africa CDC, will be officially launched to help vaccine manufacturers in Africa and support regional diversification of vaccine manufacturing.

• The event will also make the case for donors to invest in a new era of immunisation with the launch of Gavi’s investment opportunity for 2026–2030. 

• "With Team Europe, our determination to promote equitable access to global health and the health sovereignty of our African partners is growing further,” said Chrysoula Zacharopoulou, French Minister of State for Development and International Partnerships.

• "With our Alliance on track to meet almost all of the goals we set ourselves for 2025, we need also to consider how we can accelerate our progress and broaden the protection we can provide to populations for the rest of this decade. As Gavi sets these ambitious goals, I am grateful for the leadership of France, the African Union and Africa CDC as we make the case for investing in immunisation and strengthening global health security," said Professor José Manuel Barroso, Chair of the Board of Gavi, the Vaccine Alliance.

• "In 2023, Gavi marked a milestone of immunising over 1 billion children. Today, looking ahead to 2030, we have the opportunity not only to accelerate the rate at which we are protecting children, but to protect them and others from even more diseases. With the gracious support of our co-hosts, we have the best possible chance of seeing our 2030 goals realised,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. 

Geneva, 22 March 2024 – Global health and Gavi, the Vaccine Alliance stand at a crucial point. Our collective action can sustainably warrant well-being and health for our future generations. It is time to unite forces to ensure significant and long-standing progress in the fight against diseases and for enhanced primary health care in a spirit of innovation and equity.

On 20 June 2024, a high-level event co-hosted in Paris by the Government of France, the African Union and Gavi, the Vaccine Alliance, along with the support of Team Europe, will launch the African Vaccine Manufacturing Accelerator (AVMA), an initiative that will provide financial incentives to help vaccine manufacturers in Africa scale up production and become sustainable on a long-term basis. The need to ensure regional diversification of vaccine manufacturing was a key learning from the COVID-19 pandemic, when a lack of local manufacturing capacity in Africa and other parts of the world meant these countries had to wait longer for vaccines to become available. “Our determination to promote equitable access to global health and the health sovereignty of our African partners is growing further,” said Chrysoula Zacharopoulou, French Minister of State for Development and International Partnerships.

In addition, Gavi will also make the case for donors to invest in a new era of immunisation for enhanced equitable access to health care. This high-level event will bring together leaders from government, partner organisations, civil society and business for an event focused on setting out the funding Gavi will need to support and sustain immunisation from 2026 through 2030.

“In 2023, Gavi marked a milestone of immunising over 1 billion children. Today, looking ahead to 2030, we have the opportunity not only to accelerate the rate at which we are protecting children, but to protect them and others from even more diseases. With the gracious support of our co-hosts, we have the best possible chance of seeing our 2030 goals realised,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance.

The publication of Gavi’s Investment Opportunity marks a key moment in the Vaccine Alliance’s five-year cycle, kicking off a period of intense engagement with donors from government, business and philanthropies. This will culminate with a donor pledging conference targeted for end 2024 that is aimed at securing enough support from donors to fund the Alliance’s work for the following five years.

The funding enables Gavi to help more than 50 of the world’s lowest-income countries secure access to existing and new vaccines, protect communities by strengthening primary health care, shield them from the growing effects of climate change and play a foundational role in global health security. It is intricately tied to Gavi’s next strategy, Gavi 6.0, which will be approved by the Gavi Board earlier in June 2024. Although the precise details of the forthcoming Investment Opportunity are yet to be finalised, it will enable Gavi to introduce and scale up the widest portfolio of vaccines in its history – including to protect women and girls from cervical cancer with HPV vaccines, and reduce child mortality through malaria vaccines. It will also enable Gavi to protect the world from global health threats brought about by climate change, deploy new innovations, and strengthen health systems to reach more zero-dose children and missed communities.

"With our Alliance on track to meet almost all of the goals we set ourselves for 2025, we need also to consider how we can accelerate our progress and broaden the protection we can provide to populations for the rest of this decade,” said Professor José Manuel Barroso, Chair of the Board of Gavi, the Vaccine Alliance. “As Gavi sets these ambitious goals, I am grateful for the leadership of France, the African Union and Africa CDC as we make the case for investing in immunisation and strengthening global health security."

France has been a long-standing global health leader and historic champion for immunisation, with growing support for Gavi over the past 20 years, including through the innovative instrument of the International Finance Facility for Immunisation (IFFIm). This support underpins a strong commitment to innovative financing to meet the health Sustainable Development Goals (SDGs) and to support health systems in the most fragile countries. As of June 2023, France has contributed US$ 793.2 million to Gavi between 2021 and 2025, of which US$ 252.7 million were direct contributions, US$ 202.4 million were through IFFIm, and US$ 338.1 million were to the COVAX AMC. During the EU-AU Summit of February 2022, France has advocated to put access to global health as a pillar of the Euro-African Strategic Partnership, with strong support from Team Europe investments across the African continent.

The African Union spearheads Africa’s development and integration in close collaboration with African Union Member States, the Regional Economic Communities and African citizens, and Africa Centres for Disease Control and Prevention (Africa CDC) is its public health agency which supports Member States in their efforts to strengthen health systems and improve surveillance, emergency response, prevention and control of diseases. In May 2023, Gavi, the African Union and Africa CDC signed a Memorandum of Understanding, committing to increase access and accelerate the uptake of life-saving vaccines across African Union Member States, by leveraging their collective resources, expertise and expansive networks to collaboratively address a broad range of health issues.

MEDIA CONTACTS

Meg Sharafudeen
+41 79 711 55 54
msharafudeen@gavi.org

Laura Shevlin
+ 41 79 529 92 87
lshevlin@gavi.org

Share